-
Je něco špatně v tomto záznamu ?
Post-translational modifications regulate signalling by Ror1
M. Kaucká, P. Krejčí, K. Plevová, S. Pavlová, J. Procházková, P. Janovská, J. Valnohová, A. Kozubík, S. Pospíšilová, V. Bryja
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NS10439
MZ0
CEP - Centrální evidence projektů
NT11217
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
Plný text - Článek
Zdroj
Zdroj
NLK
Medline Complete (EBSCOhost)
od 2006-01-01 do Před 1 rokem
Wiley Online Library (archiv)
od 1889-01-01 do 2012-12-31
- MeSH
- B-lymfocyty metabolismus MeSH
- CHO buňky MeSH
- chronická lymfatická leukemie metabolismus MeSH
- Cricetulus MeSH
- elektroforéza v polyakrylamidovém gelu MeSH
- glykosylace MeSH
- HEK293 buňky MeSH
- imunohistochemie MeSH
- konfokální mikroskopie MeSH
- křečci praví MeSH
- lidé MeSH
- molekulová hmotnost MeSH
- posttranslační úpravy proteinů účinky léků MeSH
- průtoková cytometrie MeSH
- pseudopodia metabolismus MeSH
- signální transdukce účinky léků MeSH
- sirotčí receptory podobné receptoru tyrosinkinasy chemie genetika metabolismus MeSH
- transfekce MeSH
- transport proteinů MeSH
- ubikvitinace MeSH
- western blotting MeSH
- zvířata MeSH
- Check Tag
- křečci praví MeSH
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
AIM: In this study, we analysed the post-translational modification of receptor tyrosine kinase-like orphan receptor (Ror1). Ror1 is highly upregulated in B cells of patients with chronic lymphocytic leukaemia (CLL). Molecularly, Ror1 acts as the Wnt receptor in the non-canonical Wnt pathway. METHODS: The level of Ror1 glycosylation in HEK293 cells and in primary human CLL cells was analysed by treatment of inhibitors interfering with different steps of glycosylation process and by direct treatment of cell lysates with N-glycosidase. Ror1 ubiquitination was determined by ubiquitination assay. Functional consequences of post-translational modifications were analysed by immunohistochemistry and by analysis of cell surface proteins. Differences in Ror1 glycosylation were confirmed by analysis of 14 samples of B cells from CLL patients. RESULTS: We demonstrate that Ror1 is extensively modified by N-linked glycosylation. Glycosylation produces several variants of Ror1 with electrophoretic migration of approx. 100, 115 and 130 kDa. Inhibition of glycosylation interferes with cell surface localization of the 130-kDa variant of Ror1 and prevents Ror1-induced formation of filopodia. Moreover, we show that 130-kDa Ror1 is mono-ubiquitinated. Furthermore, individual CLL patients show striking differences in the electrophoretic migration of Ror1, which correspond to the level of glycosylation. CONCLUSION: Our data show that Ror1 undergoes complex post-translational modifications by glycosylation and mono-ubiquitination. These modifications regulate Ror1 localization and signalling, and are highly variable among individual CLL patients. These may suggest that Ror1 signals only in a subset of CLL patients despite Ror1 levels are ubiquitously high in all CLL patients.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12022075
- 003
- CZ-PrNML
- 005
- 20170413132246.0
- 007
- ta
- 008
- 120806s2011 xxk f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1111/j.1748-1716.2011.02306.x $2 doi
- 035 __
- $a (PubMed)21481194
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Kaucká, Markéta $7 _AN068807 $u Faculty of Science, Institute of Experimental Biology, Masaryk University, Kotlářská, Brno, Czech Republic.
- 245 10
- $a Post-translational modifications regulate signalling by Ror1 / $c M. Kaucká, P. Krejčí, K. Plevová, S. Pavlová, J. Procházková, P. Janovská, J. Valnohová, A. Kozubík, S. Pospíšilová, V. Bryja
- 520 9_
- $a AIM: In this study, we analysed the post-translational modification of receptor tyrosine kinase-like orphan receptor (Ror1). Ror1 is highly upregulated in B cells of patients with chronic lymphocytic leukaemia (CLL). Molecularly, Ror1 acts as the Wnt receptor in the non-canonical Wnt pathway. METHODS: The level of Ror1 glycosylation in HEK293 cells and in primary human CLL cells was analysed by treatment of inhibitors interfering with different steps of glycosylation process and by direct treatment of cell lysates with N-glycosidase. Ror1 ubiquitination was determined by ubiquitination assay. Functional consequences of post-translational modifications were analysed by immunohistochemistry and by analysis of cell surface proteins. Differences in Ror1 glycosylation were confirmed by analysis of 14 samples of B cells from CLL patients. RESULTS: We demonstrate that Ror1 is extensively modified by N-linked glycosylation. Glycosylation produces several variants of Ror1 with electrophoretic migration of approx. 100, 115 and 130 kDa. Inhibition of glycosylation interferes with cell surface localization of the 130-kDa variant of Ror1 and prevents Ror1-induced formation of filopodia. Moreover, we show that 130-kDa Ror1 is mono-ubiquitinated. Furthermore, individual CLL patients show striking differences in the electrophoretic migration of Ror1, which correspond to the level of glycosylation. CONCLUSION: Our data show that Ror1 undergoes complex post-translational modifications by glycosylation and mono-ubiquitination. These modifications regulate Ror1 localization and signalling, and are highly variable among individual CLL patients. These may suggest that Ror1 signals only in a subset of CLL patients despite Ror1 levels are ubiquitously high in all CLL patients.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a B-lymfocyty $x metabolismus $7 D001402
- 650 _2
- $a western blotting $7 D015153
- 650 _2
- $a CHO buňky $7 D016466
- 650 _2
- $a křečci praví $7 D006224
- 650 _2
- $a Cricetulus $7 D003412
- 650 _2
- $a elektroforéza v polyakrylamidovém gelu $7 D004591
- 650 _2
- $a průtoková cytometrie $7 D005434
- 650 _2
- $a glykosylace $7 D006031
- 650 _2
- $a HEK293 buňky $7 D057809
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a chronická lymfatická leukemie $x metabolismus $7 D015451
- 650 _2
- $a konfokální mikroskopie $7 D018613
- 650 _2
- $a molekulová hmotnost $7 D008970
- 650 _2
- $a posttranslační úpravy proteinů $x účinky léků $7 D011499
- 650 _2
- $a transport proteinů $7 D021381
- 650 _2
- $a pseudopodia $x metabolismus $7 D011554
- 650 _2
- $a sirotčí receptory podobné receptoru tyrosinkinasy $x chemie $x genetika $x metabolismus $7 D057050
- 650 _2
- $a signální transdukce $x účinky léků $7 D015398
- 650 _2
- $a transfekce $7 D014162
- 650 _2
- $a ubikvitinace $7 D054875
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Krejčí, Petr $7 _AN065391
- 700 1_
- $a Plevová, Karla $7 xx0158852
- 700 1_
- $a Pavlová, Šárka $7 xx0117816
- 700 1_
- $a Medalová, Jiřina $7 xx0102053
- 700 1_
- $a Janovská, Pavlína $7 mub20211103818
- 700 1_
- $a Valnohová, Jana $7 _AN068810
- 700 1_
- $a Kozubík, Alois, $d 1958- $7 mzk2004237023
- 700 1_
- $a Pospíšilová, Šárka, $d 1969- $7 xx0101843
- 700 1_
- $a Bryja, Vítězslav, $d 1977- $7 xx0035073
- 773 0_
- $w MED00154561 $t Acta physiologica $x 1748-1708 $g Roč. 203, č. 3 (2011), s. 351-362
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/21481194 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m $z 0
- 990 __
- $a 20120806 $b ABA008
- 991 __
- $a 20170413132547 $b ABA008
- 999 __
- $a ok $b bmc $g 943988 $s 779372
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2011 $b 203 $c 3 $d 351-362 $e 20110527 $i 1748-1708 $m Acta physiologica $n Acta Physiol $x MED00154561
- GRA __
- $a NS10439 $p MZ0
- GRA __
- $a NT11217 $p MZ0
- LZP __
- $a Pubmed-20120806/12/01/jt